A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells-Reference-Cited by-同舟云学术

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

Published:2009-11-05 Issue:1 Volume:24 Page:44-50
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rix U,Remsing Rix L L,Terker A S,Fernbach N V,Hantschel O,Planyavsky M,Breitwieser F P,Herrmann H,Colinge J,Bennett K L,Augustin M,Till J H,Heinrich M C,Valent P,Superti-Furga G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2009228.pdf

Reference30 articles.

1. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948–3954.

2. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926–939.

3. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.

4. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187–1189.

5. Pan J, Quintas-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S . Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci 2007; 98: 1223–1225.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Ureidocoumarin-Based Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors via Drug Repurposing Approach, Biological Evaluation, and In Silico Studies;Pharmaceuticals;2024-03-27

2. Identification of druggable regulators of cell secretion via a kinome-wide screen and high-throughput immunomagnetic cell sorting;Nature Biomedical Engineering;2023-11-27

3. Specific quinone reductase 2 inhibitors reduce metabolic burden and reverse Alzheimer’s disease phenotype in mice;Journal of Clinical Investigation;2023-10-02

4. Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges;Biochemical Pharmacology;2023-09

5. Focusing on discoidin domain receptors in premalignant and malignant liver diseases;Frontiers in Oncology;2023-03-15